|
Evaluation of clinical endpoints as surrogates for overall survival in patients treated with immunotherapies. |
|
|
Employment - Compass Therapeutics |
Leadership - Compass Therapeutics |
Honoraria - Amgen; Celldex; Compass Therapeutics; EMD Serono; Merck; Prometheus; Turnstone Bio |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celldex; Compass Therapeutics; Merck; Merck Serono; Prometheus; Turnstone Bio |
|
Research Funding - Amgen (Inst); Merck (Inst) |
Travel, Accommodations, Expenses - EMD Serono; Turnstone Bio |
|
|
Consulting or Advisory Role - GlaxoSmithKline; Novartis |
Research Funding - Astellas Pharma (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst) |
Patents, Royalties, Other Intellectual Property - Varian Medical Systems |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Adaptive Biotechnologies; Amphivena; Intensity Therapeutics |
Consulting or Advisory Role - Adaptimmune; Agonox; Alexion Pharmaceuticals; Amgen; Anaeropharma; Astellas Pharma; AstraZeneca/MedImmune; Biodesix; Bristol-Myers Squibb; Genentech/Roche; Immune Design; Immune Design; Inovio Pharmaceuticals; Janssen Oncology; Kyowa Hakko Kirin; Lilly; Lion Biotechnologies; Lycera; Merck Sharp & Dohme; Merus; Modulate Pharma; Nektar; Novartis; Omniox; pfizer; Prometheus; Seagen; Symphony Evolution; Theravance; Vaccinex |
Other Relationship - AcademicCME; Clinical Care Options; Dava Oncology; Haymarket Media; Imedex; Physicans' Education Resource; Prime Oncology; Research to Practice; TRM Oncology; Vindico |
|
|
No Relationships to Disclose |
|
|
Other Relationship - Doctor Evidence |
|
|
Research Funding - AstraZeneca (Inst) |
|
|
Research Funding - AstraZeneca (Inst) |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
Travel, Accommodations, Expenses - AstraZeneca |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
Andrea Leninka Vergara-Silva |
|
Stock and Other Ownership Interests - AstraZeneca |
Travel, Accommodations, Expenses - AstraZeneca |